Clinical Trial Update: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Carfilzomib, Lenalidomide, and Dexamethasone in Smoldering Multiple Myeloma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2022-09-13